Needham & Company maintains an 'Underperform' on Immunogen Inc. (NASDAQ: IMGN).

Needham analyst says, "We see few value-creating events in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE